ResMed Inc. (NYSE:RMD) Plans Quarterly Dividend of $0.60

ResMed Inc. (NYSE:RMD) declared a quarterly dividend on Thursday, January 29th. Investors of record on Thursday, February 12th will be given a dividend of 0.60 per share by the medical equipment provider on Thursday, March 19th. This represents a c) annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Thursday, February 12th.

ResMed has raised its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 13 years. ResMed has a dividend payout ratio of 22.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect ResMed to earn $10.36 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 23.2%.

ResMed Trading Down 2.6%

ResMed stock traded down $6.78 during trading hours on Friday, reaching $250.83. The stock had a trading volume of 370,752 shares, compared to its average volume of 914,647. The company has a fifty day simple moving average of $250.90 and a 200-day simple moving average of $263.20. ResMed has a 52 week low of $199.92 and a 52 week high of $293.81. The stock has a market cap of $36.61 billion, a PE ratio of 25.60, a PEG ratio of 1.73 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.89 and a quick ratio of 2.13.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. ResMed had a return on equity of 25.45% and a net margin of 27.35%.The firm had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the business earned $2.43 EPS. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Analysts forecast that ResMed will post 9.47 EPS for the current fiscal year.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat expectations — ResMed reported revenue of $1.423B (up 11% yoy) and non?GAAP EPS of $2.81, topping Street estimates; management cited strong demand for sleep and respiratory devices which drove margin expansion. Article Title
• Positive Sentiment: Dividend and buybacks — Board declared a $0.60 quarterly cash dividend (record Feb 12, payable Mar 19) and repurchased $175M of stock in the quarter, supporting yield and shareholder returns. Article Title
• Positive Sentiment: Margin and cash-flow improvement — Gross margin rose ~320 bps to 61.8%; operating cash flow was $340M, and non?GAAP operating income grew ~19%, indicating improved profitability and operational leverage. Article Title
• Neutral Sentiment: Product & regulatory update — Company received FDA clearance for an AI?enabled device (“Smart Comfort”) to personalize CPAP settings; promising long?term for adherence but commercial impact will accrue over time. Article Title
• Neutral Sentiment: Analyst backdrop — Multiple buy/overweight ratings and a median 6?month price target near $300 signal continued analyst support; useful context but not new catalyst. Article Title
• Negative Sentiment: Rising operating costs and one?time charges — SG&A and R&D increased (SG&A up ~12% on constant currency) and ResMed recorded $6M restructuring charges; SG&A as a percent of revenue ticked higher which could pressure margins if spending continues. Article Title
• Negative Sentiment: Insider selling — Recent filings show multiple insider sales (no purchases) over past six months; while not unusual at large caps, heavy insider selling can be viewed negatively by some investors. Article Title

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.